PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS
Volume: 21, Pages: 304 - 304
Published: Oct 1, 2010
Abstract
No abstract.
Paper Details
Title
PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS
Published Date
Oct 1, 2010
Volume
21
Pages
304 - 304
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History